Stock A069620 DAEWOONG PHARMACEUTICAL CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Daewoong Pharmaceutical Co., Ltd

Equities

A069620

KR7069620003

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-22 pm EDT 		5-day change 1st Jan Change
108,400 KRW -0.82% Intraday chart for Daewoong Pharmaceutical Co., Ltd -2.78% -7.19%
Apr. 24 Korean Sugar Imports Plunge 14% as Diabetes Cases Surge MT
Apr. 12 AEON Biopharma, Inc. announced that it has received $15 million in funding from Daewoong Pharmaceutical Co., Ltd CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,419,120 1,775,845 1,638,243 1,754,469 1,343,932 1,247,280 - -
Enterprise Value (EV) 2 1,783 2,155 2,037 1,754 1,762 1,579 1,569 1,646
P/E ratio 70.2 x 561 x 45.5 x 36.1 x 12 x 15.8 x 10.7 x 9.7 x
Yield 0.44% 0.36% 0.41% - 0.51% 0.55% 0.55% 0.97%
Capitalization / Revenue 1.41 x 1.88 x 1.55 x 1.51 x 1.1 x 0.97 x 0.91 x 0.83 x
EV / Revenue 1.77 x 2.28 x 1.93 x 1.51 x 1.44 x 1.22 x 1.14 x 1.1 x
EV / EBITDA 28.6 x 47.2 x 15.9 x 12.7 x 10.4 x 8.63 x 7.66 x 7.01 x
EV / FCF 94.4 x 27.9 x 73.4 x - 32.7 x 16.1 x 12.2 x 13.5 x
FCF Yield 1.06% 3.59% 1.36% - 3.05% 6.21% 8.2% 7.41%
Price to Book 2.57 x 3.08 x 2.79 x - 1.66 x 1.43 x 1.36 x 1.15 x
Nbr of stocks (in thousands) 10,321 10,763 11,069 11,069 11,506 11,506 - -
Reference price 3 137,500 165,000 148,000 158,500 116,800 108,400 108,400 108,400
Announcement Date 2/13/20 2/15/21 2/15/22 2/15/23 2/5/24 - - -
1KRW in Million2KRW in Billions3KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,005 944.8 1,055 1,161 1,222 1,289 1,373 1,498
EBITDA 1 62.4 45.62 128.4 138 169.1 183 204.8 235
EBIT 1 31.45 12.63 95.5 106 133.4 145 166.3 194.4
Operating Margin 3.13% 1.34% 9.05% 9.12% 10.92% 11.25% 12.11% 12.98%
Earnings before Tax (EBT) 1 16.41 -7.785 31.72 85.74 111.6 101.8 143 165.2
Net income 1 20.23 3.139 40.48 80.14 111.5 79.42 117.4 128.5
Net margin 2.01% 0.33% 3.84% 6.9% 9.12% 6.16% 8.55% 8.58%
EPS 2 1,960 294.0 3,253 4,387 9,760 6,877 10,172 11,171
Free Cash Flow 3 18,884 77,281 27,763 - 53,809 98,000 128,667 122,000
FCF margin 1,878.63% 8,180.05% 2,631.18% - 4,403.35% 7,603.09% 9,371.66% 8,144.19%
FCF Conversion (EBITDA) 30,260.08% 169,393.08% 21,618.49% - 31,826.84% 53,566.55% 62,840.86% 51,914.89%
FCF Conversion (Net income) 93,353.69% 2,462,165.05% 68,580.57% - 48,259.15% 123,386.84% 109,559.49% 94,941.63%
Dividend per Share 2 600.0 600.0 600.0 - 600.0 600.0 600.0 1,050
Announcement Date 2/13/20 2/15/21 2/15/22 2/15/23 2/5/24 - - -
1KRW in Billions2KRW3KRW in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 265.1 275.3 272.2 293.8 301.5 293.8 292.3 307.1 303 319.6 296.6 331.5 333.1 355.3 335.1
EBITDA 1 - - - 41.44 38.25 23.45 39.25 45.02 43.17 41.63 40.99 46.25 46.65 46.8 -
EBIT 1 23.92 24.71 26.77 33.57 30.31 15.3 30.97 36.19 34.2 32.04 31.23 40.6 38.5 37.4 35.3
Operating Margin 9.02% 8.97% 9.84% 11.43% 10.05% 5.21% 10.6% 11.79% 11.29% 10.03% 10.53% 12.25% 11.56% 10.53% 10.53%
Earnings before Tax (EBT) 1 20.27 20.26 24.17 27.71 28.96 4.897 27.16 31.99 26.11 26.42 13.94 35.5 33.4 32.3 30.2
Net income 1 14.48 34.85 17.52 20.74 21.51 20.38 20.47 28.76 19.76 42.5 10.83 27 25.4 24.5 22.9
Net margin 5.46% 12.66% 6.44% 7.06% 7.13% 6.93% 7% 9.37% 6.52% 13.3% 3.65% 8.14% 7.63% 6.9% 6.83%
EPS - - - - - - 1,832 - - - - - - - -
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 10/27/21 2/15/22 4/28/22 7/28/22 10/31/22 2/15/23 5/3/23 7/27/23 10/27/23 2/5/24 4/29/24 - - - -
1KRW in Billions
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 364 379 399 - 418 331 322 399
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 5.829 x 8.317 x 3.106 x - 2.472 x 1.812 x 1.571 x 1.698 x
Free Cash Flow 2 18,884 77,281 27,763 - 53,809 98,000 128,667 122,000
ROE (net income / shareholders' equity) 3.71% 0.56% 6.01% - 15.2% 9.3% 13% 12.5%
ROA (Net income/ Total Assets) 1.86% 0.27% 2.93% - 7.59% 5.72% 7.25% 7.1%
Assets 1 1,088 1,143 1,383 - 1,470 1,389 1,620 1,810
Book Value Per Share 3 53,580 53,521 53,015 - 70,283 75,555 79,463 93,890
Cash Flow per Share 3 3,681 9,225 4,357 - 11,604 12,002 14,193 14,083
Capex 1 19.1 21.1 20.2 - 78.8 61.3 51.1 66.5
Capex / Sales 1.9% 2.23% 1.91% - 6.45% 4.76% 3.72% 4.44%
Announcement Date 2/13/20 2/15/21 2/15/22 2/15/23 2/5/24 - - -
1KRW in Billions2KRW in Million3KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Daewoong Pharmaceutical Co., Ltd

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

1st Jan change Capi.
DAEWOONG PHARMACEUTICAL CO., LTD Stock Daewoong Pharmaceutical Co., Ltd
-7.19% 921M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+18.71% 44.35B
SANDOZ GROUP AG Stock Sandoz Group AG
+19.44% 15.08B
CIPLA LIMITED Stock Cipla Limited
+19.49% 14.37B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+57.58% 13.06B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-9.70% 6.75B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+12.55% 5.64B
RICHTER GEDEON VEGYÉSZETI GYÁR NYILVÁNOSAN MUKÖDO RT. Stock Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.
+4.00% 4.66B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A069620 Stock
  4. Financials Daewoong Pharmaceutical Co., Ltd